Prognostic Factors in Colorectal Cancer Outcomes

Prognosis in colorectal cancer is determined by an interplay of anatomical, cellular and molecular variables. Tumour stage at diagnosis remains the strongest predictor of survival, but variation within each stage has prompted investigation of additional clinicopathological factors such as lymphovascular invasion, perineural invasion and tumour budding. Molecular biomarkers—including microsatellite instability, tumour mutation burden and key driver mutations in KRAS, BRAF and TP53—further refine risk stratification. Host characteristics, such as systemic inflammatory markers and patient age, also modulate outcomes. Tumour location (right- versus left-sided) introduces distinct genetic and immunological profiles that influence recurrence risk and therapeutic response. The tumour microenvironment, notably the density of stromal elements and degree of lymphocytic infiltration, has emerged as an independent determinant of relapse. Circulating proteins and antigens measured before surgery offer minimally invasive prognostic information. Together, these factors support personalised staging and guide decisions on adjuvant therapy, surveillance intensity and enrolment in clinical trials, with the aim of improving global survival rates and optimising resource allocation.

Research from Nature Portfolio

Recent work has mapped the dynamic behaviour of individual metastatic lesions in thousands of patients, revealing four distinct response-progression phenotypes that vary according to organ site. Analysis of serial imaging data showed that the sequence of progression among liver, lung and lymph node metastases correlates strongly with long-term survival, with first progression in the liver portending a poorer outcome. These findings underscore the need for organ-specific therapeutic strategies and for incorporating lesion-level response patterns into prognostic models.

Prognostic Factors in Colorectal Cancer Outcomes publication trend

The graph below shows the total number of articles in prognostic factors in colorectal cancer outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Lesion-specific heterogeneity: Variation in treatment response and growth dynamics among individual metastatic deposits.

Disease-free survival (DFS): Interval from primary treatment to the first documented recurrence or death from any cause.

Perineural invasion (PNI): Infiltration of cancer cells along or around nerve fibres within the tumour.

Carcinoembryonic antigen (CEA): A glycoprotein measured in blood that can be elevated in colorectal malignancy.

Desmoplastic reaction (DR): The fibrotic stromal response at the invasive front of a tumour, classified by collagen and myxoid features.

References

1. Pathological Features and Prognostication in Colorectal Cancer. Current Oncology (2021).
2. Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. Nature Communications (2023).
3. Survival outcomes of stage I colorectal cancer: development and validation of the ACEPLY model using two prospective cohorts. BMC Medicine (2023).
4. Histopathology and levels of proteins in plasma associate with survival after colorectal cancer diagnosis. British Journal of Cancer (2023).
5. Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial). British Journal of Cancer (2021).